|
Marching on to March events
|
1
|
Zenith Epigenetics
|
Feb 14, 2018 05:50PM
|
|
Mark Day interview with Stock News Now
|
4
|
BIOASIS TECHNOLOGIES INC
|
Feb 27, 2019 01:53PM
|
|
Mark Day Panelist at RESI 2017 Early Stage Therapeutics Panel
|
1
|
BIOASIS TECHNOLOGIES INC
|
Sep 23, 2017 05:30PM
|
|
MarkDayCEO1 comment on WuXi collaboration
|
1
|
BIOASIS TECHNOLOGIES INC
|
May 22, 2018 02:36PM
|
|
MD&A
|
4
|
Resverlogix Corp.
|
Mar 12, 2019 02:22PM
|
|
MD&A and Financials
|
3
|
BIOASIS TECHNOLOGIES INC
|
Jul 28, 2019 08:27AM
|
|
MD&A and Financials are posted
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jul 30, 2018 11:24PM
|
|
MD&A and Financials Sept 16, 2019
|
4
|
Resverlogix Corp.
|
Sep 16, 2019 09:08PM
|
|
MD&A and Financials up on SEDAR
|
5
|
Resverlogix Corp.
|
Mar 17, 2018 02:11PM
|
|
MD&A March 26, 2018
|
8
|
Zenith Epigenetics
|
Mar 27, 2018 06:35PM
|
|
Medimmune fusion proteins described in Q2 update
|
2
|
BIOASIS TECHNOLOGIES INC
|
Aug 02, 2016 11:50AM
|
|
Melanotransferrin receptor vs. Transferrin Recepor
|
4
|
BIOASIS TECHNOLOGIES INC
|
Jul 02, 2018 03:25PM
|
|
Merck lands positive PhIII for its CETP drug anacetrapib
|
1
|
Resverlogix Corp.
|
Jun 27, 2017 08:42AM
|
|
Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
|
8
|
Zenith Epigenetics
|
Sep 01, 2018 10:59PM
|
|
More BET Publications and New Indications
|
1
|
Zenith Epigenetics
|
Dec 28, 2018 05:14PM
|
|
More confirmation of BETonMACE commencing/enrolling in Fall 2015
|
3
|
Resverlogix Corp.
|
Jul 28, 2015 09:38PM
|
|
More sites now recruiting for ZEN003694 NCT02705469 trial
|
4
|
Zenith Epigenetics
|
Jun 09, 2016 01:27PM
|
|
Morphic Holding
|
|
BIOASIS TECHNOLOGIES INC
|
Mar 04, 2021 11:37AM
|
|
Nature Reviews Disease Primer on Atherosclerosis
|
4
|
Resverlogix Corp.
|
Aug 19, 2019 10:42AM
|
|
NCT03901469: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)
|
6
|
Zenith Epigenetics
|
Apr 08, 2019 07:40AM
|
